SHIFT Newsroom · GLOBAL
How obesity medicines have developed: a narrative review
This narrative review traces the development of obesity medicines and discusses named treatments. It summarises existing evidence rather than reporting a new clinical trial. Medicine-specific results, limitations and current UK access should be checked separately.
What the source says
This narrative review traces the development of obesity medicines and discusses named treatments. It summarises existing evidence rather than reporting a new clinical trial. Medicine-specific results, limitations and current UK access should be checked separately.
Evidence and limits
The review discusses the development, efficacy and safety of named obesity medicines, including semaglutide and tirzepatide. The earlier statement that medicine details were unavailable was too broad. Any individual outcome or UK access question needs medicine-specific evidence.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
Medicine names and population averages are a starting point for understanding the options. They are not a personal forecast or proof of current UK availability.
Known facts
- This narrative review traces the development of obesity medicines and discusses named treatments.